Tag Archive for: Genmab

Merus headquarters in Utrecht, The NetherlandsMerus NV
M&A

Genmab swallows Merus in US$8bn deal

Danish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab

Read more
Antibodies get a second life with the right attachment (payload) (©Genmab A/S, Valby)
Financing

Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio

Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).

Read more
agenX
Collaboration

Genmab and argenx combine antibody know-how

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.

Read more